• PCV68 PREDICTORS OF FAILURE-TO-RESCUE FOR ACUTE MYOCARDIAL INFARCTION

    May 1, 2020, 00:00

  • PMU39 COOKING AT HOME CAN SAVE MONEY, REGARDLESS OF FOOD PRICE: A MULTILEVEL ANALYSIS OF MEALS PREPARED AWAY FROM THE HOME ON DIET MEASURES AND FOOD EXPENDITURES

    May 1, 2020, 00:00

  • PMH59 COMPLEX EXAMINATION OF THE MENTAL HEALTH OF TEACHERS

    May 1, 2020, 00:00

  • PCV76 IDENTIFYING KNOWLEDGE GAPS IN HEART FAILURE (HF) RESEARCH AMONG WOMEN USING UNSUPERVISED MACHINE LEARNING METHODS

    May 1, 2020, 00:00

  • PDG3 EVALUATION OF PROGESTERONE (17-ALPHA HYDROXYPROGESTERONE CAPROATE (17-OHPC)) UTILIZATION, ADHERENCE, AND OUTCOMES IN WOMEN WITH A HIGH-RISK PREGNANCY

    May 1, 2020, 00:00

  • PMS52 EPIDEMIOLOGY OF DERMATITIS ATOPIC IN AMERICA: SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • PMD30 HETEROGENEITY OF PATIENTS TREATED WITH MULTI-PLANAR SOFTWARE-ASSISTED EXTERNAL FIXATION SYSTEMS (SPATIAL FRAMES) - ANALYSES OF PATIENT VARIABILITY AND OPERATIVE COMPLICATIONS

    May 1, 2020, 00:00

  • PDB95 FACTORS ASSOCIATED WITH MEDICATION NON-ADHERENCE AMONG MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES

    May 1, 2020, 00:00

  • PBI20 COMPARISON OF DECISION MODELING APPROACHES FOR HEALTH TECHNOLOGY AND POLICY EVALUATION

    May 1, 2020, 00:00

  • PDG47 OUTPATIENT OPIOID PRESCRIBING AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS OF NATIONAL AMBULATORY MEDICAL CARE SURVEY, 2011-2016

    May 1, 2020, 00:00

  • PDB65 EPIDEMIOLOGICAL DISEASE BURDEN OF NON-INSULIN-DEPENDENT DIABETES WITH COMPLICATIONS BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PDB18 ASSESSMENT OF THE HEALTH CARE UTILIZATION AND ECONOMIC BURDEN ON DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE US VETERANS HEALTH ADMINISTRATION POPULATION

    May 1, 2020, 00:00

  • PMS3 LORECEVIVINT, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS: FACTORS DRIVING WOMAC PAIN SUBSCORE CHANGES - A POST HOC ANALYSIS OF PHASE 2B DATA

    May 1, 2020, 00:00

  • PCN15 EFFICACY, EFFECTIVENESS, AND SAFETY OF FRONTLINE TREATMENTS FOR PERIPHERAL T-CELL LYMPHOMA

    May 1, 2020, 00:00

  • PMD53 COMPARISON OF WOUND CLOSURE IN SURGICAL WOUNDS BETWEEN SINGLE-USE NEGATIVE PRESSURE WOUND THERAPY AND TRADITIONAL NEGATIVE PRESSURE WOUND THERAPY: A REAL WORLD ANALYSIS

    May 1, 2020, 00:00

  • Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials

    May 1, 2020, 00:00

  • PIH82 PREVALENCE AND PREDICTORS OF POLYPHARMACY AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN A LARGE COMMUNITY-DWELLING OLDER POPULATION IN ITALY

    May 1, 2020, 00:00

  • PCN13 FACTORS THAT MODIFY THE EFFECT OF MONO- OR COMBINATION PD-1/PD-L1 INHIBITOR THERAPIES ON SURVIVAL OUTCOMES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00

  • PMH23 ECONOMIC BURDEN OF SCHIZOPHRENIA AMONG YOUNG ADULTS WITH MEDICAID COVERAGE

    May 1, 2020, 00:00

  • PBI31 MANAGED ENTRY AGREEMENTS FOR ATMPS DESPITE ACCESS ALREADY GRANTED? THE CASE OF GERMANY

    May 1, 2020, 00:00

  • PIN73 KNOWLEDGE OF TUBERCULOSIS AMONG PATENT AND PROPRIETARY MEDICINE VENDORS IN RURAL AREAS OF ENUGU STATE IN SOUTHEAST NIGERIA

    May 1, 2020, 00:00

  • PMU41 PREVALENCE AND ASSOCIATED FACTORS TO SUICIDE ATTEMPTS IN LOW-INCOME ADOLESCENTS FROM THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PDG10 COST-EFFECTIVENESS OF CELECOXIB VERSUS IBUPROFEN AND NAPROXEN IN PATIENTS WITH OSTEOARTHRITIS IN UNITED ARAB EMIRATES AND SAUDI ARABIA BASED ON RESULTS FROM THE PRECISION TRIAL

    May 1, 2020, 00:00

  • PMH60 SURVEY OF PATIENT EXPERIENCE AND BURDEN OF ILLNESS IN WOMEN WITH POSTPARTUM DEPRESSION

    May 1, 2020, 00:00

  • PMS34 TALTZ® (IXEKIZUMAB) FOR TREATMENT OF PSORIATIC ARTHRITIS IN THE UNITED STATES: A BUDGET IMPACT ANALYSIS

    May 1, 2020, 00:00

  • PDB53 TRENDS IN PRICES OF INSULIN MARKETED IN THE US (1984-2020)

    May 1, 2020, 00:00

  • PIN35 UTILIZATION, SPENDING AND PRICE TRENDS FOR ANTIVIRAL (FLU AGENTS) IN THE US MEDICAID PROGRAMS: EMPIRICAL DATA ANALYSIS FROM 1999-2018.

    May 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Real World Data Information Systems

    May 1, 2020, 00:00

  • PIH27 DIAGNOSING NEWBORNS WITH SUSPECTED SEVERE MITOCHONDRIAL DISORDERS: A COST-EFFECTIVENESS STUDY COMPARING EARLY WHOLE EXOME SEQUENCING TO STANDARD OF CARE

    May 1, 2020, 00:00

  • PCN9 TARGETED LITERATURE REVIEW (TLR) OF THE REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG MCRPC PATIENTS IN THE US

    May 1, 2020, 00:00

  • PIH36 TIME TO CONFIRMATORY TESTING OF CHILDREN AGE 72 MONTHS FOR ELEVATED BLOOD LEAD

    May 1, 2020, 00:00

  • AI2 PREDICTORS OF PARKINSON DISEASE IN A MEDICARE POPULATION: AN APPLICATION OF MACHINE LEARNING IN EARLY DISEASE DETECTION

    May 1, 2020, 00:00

  • PMU16 IN-HOSPITAL OUTCOMES ASSOCIATED WITH HEART FAILURE AMONG WOMEN WITH BREAST CANCER IN THE U.S.: AN ANALYSIS OF THE 2012-2016 NATIONAL INPATIENT SAMPLE

    May 1, 2020, 00:00

  • PMH13 ANALYZING TRENDS IN MEDICAL EXPENDITURES ASSOCIATED WITH ALZHEIMER'S DISEASE AMONG U.S. ADULTS WITH DIABETES: 2013-2017

    May 1, 2020, 00:00

  • PMD45 COMPARISON OF WOUND CLOSURE IN CHRONIC LOWER EXTREMITY ULCERS BETWEEN SINGLE-USE NEGATIVE PRESSURE WOUND THERAPY AND TRADITIONAL NEGATIVE PRESSURE WOUND THERAPY: A REAL WORLD ANALYSIS

    May 1, 2020, 00:00

  • PDG48 PRESCRIBING PRACTICES FOR HYPERLIPIDEMIA AMONG U.S. AMBULATORY PATIENTS

    May 1, 2020, 00:00

  • PDG63 FACTORS ASSOCIATED WITH SLEEPING MEDICATION USE AMONG ADULTS IN THE UNITED STATES

    May 1, 2020, 00:00

  • PDB97 DISEASE STATE AWARENESS AND ITS IMPACT ON DISEASE MANAGEMENT IN PATIENTS WITH TYPE 2 DIABETES IN QUETTA, PAKISTAN.

    May 1, 2020, 00:00

  • PDG20 HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS: A SEER-MEDICARE ANALYSIS

    May 1, 2020, 00:00

  • PDB4 SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF THE EFFECT OF NALTREXONE/ BUPROPION COMPARED WITH OTHER ANTI-OBESITY DRUGS IN OVERWEIGHT AND OBESE PATIENTS

    May 1, 2020, 00:00

  • PMD28 PERIOPERATIVE OUTCOME COMPARISON FOLLOWING UNILATERAL AND SIMULTANEOUS BILATERAL TOTAL KNEE ARTHROPLASTY

    May 1, 2020, 00:00

  • PMS6 EFFECTIVENESS AND ACCEPTABILITY OF AMITRIPTYLINE AND FOOD AND DRUG ADMINISTRATION-APPROVED TREATMENTS FOR FIBROMYALGIA: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00

  • PIH63 THE EFFICACY OF TREATMENTS FOR ATOPIC DERMATITIS IN CHILDREN: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00

  • PAM11 DEVELOPMENT AND EVALUATION OF THE BLOOD DEFICIENCY QUESTIONNAIRE (BDQ)

    May 1, 2020, 00:00

  • PDG7 COST-EFFECTIVENESS ANALYSIS OF SULODEXIDE VERSUS DIOSMIN IN THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY IN CHINA

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Health Policy Regulatory

    May 1, 2020, 00:00

  • PMU7 IS THE TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION FIT-FOR-PURPOSE?: A MIXED-METHODS APPROACH

    May 1, 2020, 00:00

  • PIN7 REAL-WORLD EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS (DAA) IN YOUNG ADULT (18-25) AND ELDERLY (80+) POPULATIONS WITH HEPATITIS C (HCV)

    May 1, 2020, 00:00

  • PIH44 EPIDEMIOLOGICAL DISEASE BURDEN OF FEMALE INFERTILITY BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • Cost-Effectiveness Studies

    May 1, 2020, 00:00

  • PDG57 EFFICACY AND SAFETY OF FLAVONOIDS IN ADULT PATIENTS WITH HEMORRHOIDS: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Patient-Centered Research

    May 1, 2020, 00:00

  • Individual's Health - Methodological Statistical Research

    May 1, 2020, 00:00

  • PMS95 RHEUMATOID ARTHRITIS TREATMENT PROFILE IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

    May 1, 2020, 00:00

  • PIN36 BUDGETARY IMPACT ANALYSIS OF PREEXPOSURE PROPHYLAXIS (PREP) STRATEGY FOR THE PREVENTION OF HIV IN COLOMBIA, 2019-2021

    May 1, 2020, 00:00

  • CC2 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING AND TREATMENT FOR SPINAL MUSCULAR ATROPHY

    May 1, 2020, 00:00

  • PMD54 COMPARISON OF WOUND CLOSURE IN PRESSURE ULCERS BETWEEN SINGLE-USE NEGATIVE PRESSURE WOUND THERAPY AND TRADITIONAL NEGATIVE PRESSURE WOUND THERAPY: A REAL WORLD ANALYSIS

    May 1, 2020, 00:00

  • PDB24 ANNUAL HEALTH INSURANCE TREATMENT COST OF NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH NEUROLOGICAL COMPLICATIONS BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00

  • PCV56 COMPARISON OF THE FRAMINGHAM, PROCAM AND MODIFIED FRAMINGHAM RISK SCORES FOR PREDICTING CARDIOVASCULAR EVENTS IN A COHORT FROM A CARDIOVASCULAR PREVENTION PROGRAM IN THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • Gastrointestinal Disorders - Methodological Statistical Research

    May 1, 2020, 00:00

  • PB2 ADHERENCE TO INJECTABLE ANTIDIABETIC THERAPIES (IAT) AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CHINA: RESULTS FROM A CROSS-SECTIONAL SURVEY STUDY

    May 1, 2020, 00:00

  • Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing

    May 1, 2020, 00:00

  • PMS25 CLINICAL VALIDATION OF A BUDGET IMPACT MODEL USING THE ESTABLISHED KEY OPINION LEADER VALIDATION FRAMEWORK (KOLVF)

    May 1, 2020, 00:00

  • PMH56 FITTING ITEM RESPONSE THEORY MODEL TO DETERMINE THE PSYCHOMETRIC PROPERTIES OF KESSLER PSYCHOLOGICAL DISTRESS SCALE AMONG WOMEN WHO EXCHANGE SEX

    May 1, 2020, 00:00

  • PIN90 COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM

    May 1, 2020, 00:00

  • PIN14 UPDATING THE CMS MAJOR DIAGNOSTIC CATEGORIES (MDC) TO ALIGN WITH A PATHOPHYSIOLOGICAL MODEL OF DISEASE: IMPLICATIONS FOR RESEARCH AND CLINICAL CARE RESOURCE ALLOCATION

    May 1, 2020, 00:00

  • PDG15 ECONOMIC ASSESSMENT OF SWITCHING FROM DIPEPTIDYL PEPTIDASE-4 INHIBITORS TO SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS OR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USING REAL-WORLD DATA

    May 1, 2020, 00:00

  • Infectious Diseases - Methodological Statistical Research

    May 1, 2020, 00:00

  • PDG29 DROSPIRENONE INDUCED GALL BLADDER DISEASES: A RETROSPECTIVE STUDY OF EUDRAVIGILANCE DATABASE

    May 1, 2020, 00:00

  • PMU8 EVALUATION OF THE IMPACT OF AN INPATIENT DISCHARGE CARE PLANNING INTERVENTION ON HOSPITAL 30-DAY READMISSIONS AND COSTS IN A MEDICARE POPULATION

    May 1, 2020, 00:00

  • PIN57 UPTAKE OF PRE-EXPOSURE PROPHYLAXIS (PREP) AND TYPE OF PROVIDERS AMONG COMMERCIALLY-INSURED PERSONS IN THE UNITED STATES, 2012-2018

    May 1, 2020, 00:00

  • Injury Regulatory

    May 1, 2020, 00:00

  • Infectious Diseases - Epidemiology Public Health

    May 1, 2020, 00:00

  • PMH33 VARIATION IN TREATMENT PERSISTENCE BETWEEN ACUTE AND CHRONIC OPIOID USERS RECEIVING BUPRENORPHINE PRODUCTS FOR OPIOID USE DISORDER

    May 1, 2020, 00:00

  • PIH10 COST-EFFECTIVENESS ANALYSIS OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN OSTEOARTHRITIS IN CHINA

    May 1, 2020, 00:00

  • Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling

    May 1, 2020, 00:00

  • Multiple Diseases - Health Policy Regulatory

    May 1, 2020, 00:00

  • PMU56 IMPACT OF FDA APPROVAL OF NEW AGENTS ON THERAPEUTIC OPTIONS FOR GENETIC VARIANTS IN PEDIATRIC TUMORS

    May 1, 2020, 00:00

  • PDG56 APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN CHINA NATIONAL REIMBURSEMENT DRUG LIST PRICE NEGOTIATIONS: THE EVOLVING TREND AND IMPLICATIONS

    May 1, 2020, 00:00

  • PDG14 BUDGET IMPACT ANALYSIS OF GIPAP AND VPAP TERMINATION WITHIN THE NEXT 5 YEARS IN VIETNAM

    May 1, 2020, 00:00

  • PIH20 OUTCOME AND ECONOMIC EVALUATION OF NEONATAL SCREENING USING MS/MS FOR INHERITED METABOLIC DISEASES

    May 1, 2020, 00:00

  • PIN19 A COST EFFECTIVENESS ANALYSIS OF ACTIVE CASE FINDING AND PASSIVE CASE FINDING FOR CASE DETECTION OF TUBERCULOSIS AT KISUGU HC III,KAMPALA UGANDA.

    May 1, 2020, 00:00

  • Alternative Medicine Nutrition - Economic Evaluation

    May 1, 2020, 00:00

  • Individual's Health - Real World Data Information Systems

    May 1, 2020, 00:00

  • PMH8 EFFECT OF DEPRESSION ON WORK PRODUCTIVITY COSTS AND EMPLOYMENT

    May 1, 2020, 00:00

  • PMU65 EVALUATION OF HOME HEALTH FOR PATIENTS ELIGIBLE FOR THE POST-ACUTE CARE TRANSFER POLICY

    May 1, 2020, 00:00

  • PIH47 DEMENTIA SEVERITY AND OPIOID USE IN LONG-TERM CARE NURSING HOME RESIDENTS

    May 1, 2020, 00:00

  • PMH12 TRAJECTORY IN HYPNOTIC DRUG USE, SELF-PERCEIVED HEALTH, AND HEALTHCARE EXPENDITURES AMONG PATIENTS DIAGNOSED WITH ANXIETY DISORDERS

    May 1, 2020, 00:00

  • PDB69 FACTORS ASSOCIATED WITH PRE-DIABETES IN THE U.S ‘DIABETES-BELT’ REGION POPULATION

    May 1, 2020, 00:00

  • Mental Health - Methodological Statistical Research

    May 1, 2020, 00:00

  • PIH42 RECURRENT VAGINITIS AND CANDIDIASIS: BURDEN AMONG COMMERCIALLY INSURED WOMEN WITH TYPE II DIABETES IN THE US

    May 1, 2020, 00:00

  • PIH58 GEOGRAPHICAL DISPARITIES IN NON-UTILIZATION OF HEALTH FACILITY DELIVERY AND POSTNATAL SERVICES IN GHANA

    May 1, 2020, 00:00

  • PMU45 FACTORS ASSOCIATED WITH NEGATIVE SELF RATED HEALTH (SRH) IN A PRIVATE HEALTH PLAN IN BRAZIL

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Real World Data Information Systems

    May 1, 2020, 00:00

  • PMS58 EPIDEMIOLOGICAL DISEASE BURDEN OF INJURIES TO THE ELBOW AND FOREARM BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PMH46 GEOGRAPHIC VARIATION IN TREATMENT ADMISSIONS FOR OPIOID USE DISORDER IN CINCINNATI COMPARED TO THE UNITED STATES

    May 1, 2020, 00:00

  • PGI21 COST PER ACCEPTABLE LIFE-YEARS AND COST PER QALY GAINS IN NON-ACCEPTABLE HEALTH STATE FOR BIOLOGICAL TREATMENT IN CROHN'S DISEASE, A NOVEL APPROACH IN HEALTH ECONOMIC MODELLING

    May 1, 2020, 00:00

  • PGI36 ESTIMATION OF THE MINIMAL IMPORTANT DIFFERENCES IN EUROQOL-5 DIMENSIONS (EQ-5D) FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION

    May 1, 2020, 00:00

  • PIN8 HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL

    May 1, 2020, 00:00

  • PMD32 RISK AND OUTCOMES FOLLOWING APPLICATION OF MULTI-PLANAR RING FIXATION SYSTEMS - A TWELVE YEAR REVIEW FROM A US CLAIMS DATABASE ANALYSIS

    May 1, 2020, 00:00

  • Advanced Analytics Studies

    May 1, 2020, 00:00

  • PDB68 CHARACTERISTICS OF PATIENTS WITH SEVERE HYPOGLYCEMIA AMONG PATIENTS WITH DIABETES USING INSULIN IN COMMERCIALLY INSURED, MEDICARE, AND MEDICAID POPULATION

    May 1, 2020, 00:00

  • PMU20 A DEVICE CATEGORY-BASED ECONOMIC MODEL EXPLORING ELECTROSURGERY TECHNOLOGIES ACROSS PROCEDURE TYPES: A UNITED STATES ANALYSIS

    May 1, 2020, 00:00

  • PIH21 EFFICACY AND SAFETY OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN PATIENTS WITH OSTEOARTHRITIS: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00

  • PMS7 THE ROLE OF SPECIALIZED PRO-RESOLVING LIPID MEDIATORS IN THE TREATMENT OF INFLAMMATION CAUSED BY EXERCISING: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • PIN20 SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEPATITIS C

    May 1, 2020, 00:00

  • Medical Devices - Health Policy Regulatory

    May 1, 2020, 00:00

  • PDG41 CLOSURE OF THE PART D COVERAGE GAP AND OUT-OF-POCKET COSTS FOR RHEUMATOID ARTHRITIS BIOLOGICS IN MEDICARE PART D

    May 1, 2020, 00:00

  • Editorial Board

    Apr 21, 2020, 08:38

  • Public Attitudes on Lung Cancer Screening and Radiation Risk: A Best-Worst Experiment

    Apr 1, 2020, 00:00

  • Is There a Future for Value-Based Contracting? [Editor's Choice]

    Apr 1, 2020, 00:00

  • A Systematic Review of the Feasibility and Psychometric Properties of the ICEpop CAPability Measure for Adults and Its Use So Far in Economic Evaluation

    Apr 1, 2020, 00:00

  • Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France

    Apr 1, 2020, 00:00

  • Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report [Editor's Choice]

    Apr 1, 2020, 00:00

  • Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications

    Apr 1, 2020, 00:00

  • Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts

    Apr 1, 2020, 00:00

  • Are Value-Based Arrangements the Answer We’ve Been Waiting for?

    Apr 1, 2020, 00:00

  • Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match? [Editor's Choice]

    Apr 1, 2020, 00:00

  • Table of Contents

    Apr 1, 2020, 00:00

  • Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users

    Apr 1, 2020, 00:00

  • Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim

    Apr 1, 2020, 00:00

  • Reporting Quality of Discrete Event Simulations in Healthcare—Results From a Generic Reporting Checklist

    Apr 1, 2020, 00:00

  • Copyright/Subscription

    Apr 1, 2020, 00:00

  • Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead

    Apr 1, 2020, 00:00

  • Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

    Apr 1, 2020, 00:00

  • Managed Entry Agreements: Policy Analysis From the European Perspective [Editor's Choice]

    Apr 1, 2020, 00:00

  • Editorial Board

    Mar 18, 2020, 10:02

  • Author's Reply

    Mar 1, 2020, 00:00

  • Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis

    Mar 1, 2020, 00:00

  • Socioeconomic Status of Newborns and Hospital Efficiency: Implications for Hospital Payment Methods

    Mar 1, 2020, 00:00

  • How Are Debriefing Questions Used in Health Discrete Choice Experiments? An Online Survey

    Mar 1, 2020, 00:00

  • Mapping WOMAC Onto the EQ-5D-5L Utility Index in Patients With Hip or Knee Osteoarthritis

    Mar 1, 2020, 00:00

  • Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?

    Mar 1, 2020, 00:00

  • Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting [Editor's Choice]

    Mar 1, 2020, 00:00

  • Moving Beyond the Tip of the Iceberg to Incorporate Patients’ Perspectives and Outcomes in the Medical Device Regulatory Process

    Mar 1, 2020, 00:00

  • Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation

    Mar 1, 2020, 00:00

  • Table of Contents

    Mar 1, 2020, 00:00

  • Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs [Editor's Choice]

    Mar 1, 2020, 00:00

  • Measuring Quality-Adjusted Life-Years When Health Fluctuates

    Mar 1, 2020, 00:00

  • Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force [Editor's Choice]

    Mar 1, 2020, 00:00

  • Psychometric Analysis of the Abdominal Score From the Diary for Irritable Bowel Syndrome Symptoms–Constipation Using Phase IIb Clinical Trial Data

    Mar 1, 2020, 00:00

  • A Step Closer to Better Research Prioritization? The ISPOR Value of Information Task Force Reports

    Mar 1, 2020, 00:00

  • Subscription Page

    Mar 1, 2020, 00:00

  • Letter to the Editor: Methods for Measuring Multiple Medication Adherence: A Systematic Review

    Mar 1, 2020, 00:00

  • Integrating the Voice of the Patient Into the Medical Device Regulatory Process Using Patient Preference Information

    Mar 1, 2020, 00:00

  • Computing PROPr Utility Scores for PROMIS® Profile Instruments

    Mar 1, 2020, 00:00

  • Economic Evaluation of User-Fee Exemption Policies for Maternal Healthcare in Burkina Faso: Evidence From a Cost-Effectiveness Analysis

    Mar 1, 2020, 00:00

  • Exploratory Factor Analysis of a Patient-Centered Cancer Care Measure to Support Improved Assessment of Patients’ Experiences

    Mar 1, 2020, 00:00

  • Editorial Board

    Feb 27, 2020, 10:34

  • Health-Related Quality of Life in Children With Low Language or Congenital Hearing Loss, as Measured by the PedsQL and Health Utility Index Mark 3

    Feb 1, 2020, 00:00

  • Value-Based Pharmaceutical Contracts: Value for Whom?

    Feb 1, 2020, 00:00

  • Copyright/Subscription

    Feb 1, 2020, 00:00

  • Why Reinvent the Wheel? Use or Modification of Existing Clinical Outcome Assessment Tools in Medical Product Development [Editor's Choice]

    Feb 1, 2020, 00:00

  • Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

    Feb 1, 2020, 00:00

  • A Head-On Ordinal Comparison of the Composite Time Trade-Off and the Better-Than-Dead Method

    Feb 1, 2020, 00:00

  • Table of Contents

    Feb 1, 2020, 00:00

  • Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana

    Feb 1, 2020, 00:00

  • Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example

    Feb 1, 2020, 00:00

  • Clinical Effectiveness of Decision Support for Prescribing Opioids for Chronic Noncancer Pain: A Prospective Cohort Study

    Feb 1, 2020, 00:00

  • Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation

    Feb 1, 2020, 00:00

  • Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems [Editor's Choice]

    Feb 1, 2020, 00:00

  • Optimal Design of Population-Level Financial Incentives of Influenza Vaccination for the Elderly

    Feb 1, 2020, 00:00

  • “Stick or Twist?” Negotiating Price and Data in an Era of Conditional Approval

    Feb 1, 2020, 00:00

  • What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis

    Feb 1, 2020, 00:00

  • Effects of Lean Healthcare on Patient Flow: A Systematic Review

    Feb 1, 2020, 00:00

  • Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions [Editor's Choice]

    Feb 1, 2020, 00:00

  • To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland

    Feb 1, 2020, 00:00

  • Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force

    Feb 1, 2020, 00:00

  • Author's Reply

    Feb 1, 2020, 00:00

  • Editorial Board

    Jan 15, 2020, 08:20

  • Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review

    Jan 1, 2020, 00:00

  • Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review

    Jan 1, 2020, 00:00

  • Copyright/Subscription

    Jan 1, 2020, 00:00

  • Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations

    Jan 1, 2020, 00:00

  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

    Jan 1, 2020, 00:00

  • Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System

    Jan 1, 2020, 00:00

  • Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis [Editor's Choice]

    Jan 1, 2020, 00:00

  • A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C

    Jan 1, 2020, 00:00

  • Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary

    Jan 1, 2020, 00:00

  • Costs and Benefits of Alternative Strategies to Control the Spread of Livestock-Acquired Methicillin-Resistant Staphylococcus Aureus From Pig Production

    Jan 1, 2020, 00:00

  • HTA Around the World: Broadening Our Understanding of Cross-Country Differences [Editor's Choice]

    Jan 1, 2020, 00:00

  • Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis [Editor's Choice]

    Jan 1, 2020, 00:00

  • Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands

    Jan 1, 2020, 00:00

  • Table of Contents

    Jan 1, 2020, 00:00

  • Development of System Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada

    Jan 1, 2020, 00:00

  • Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?

    Jan 1, 2020, 00:00

  • Concepts and Instruments for Patient-Reported Outcome Assessment in Celiac Disease: Literature Review and Experts’ Perspectives

    Jan 1, 2020, 00:00

  • The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review

    Jan 1, 2020, 00:00

  • Disclosure Information

    Dec 17, 2019, 09:25

  • Editorial Board

    Dec 3, 2019, 08:15

  • Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

    Dec 1, 2019, 00:00

  • Table of Contents

    Dec 1, 2019, 00:00

  • Excess Costs and Economic Burden of Obesity-Related Cancers in the United States [Editor's Choice]

    Dec 1, 2019, 00:00

  • Measuring Productivity Costs in Patients With Musculoskeletal Disorders: Measurement Properties of the Institute for Medical Technology Assessment Productivity Cost Questionnaire

    Dec 1, 2019, 00:00

  • Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study

    Dec 1, 2019, 00:00

  • How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L [Editor's Choice]

    Dec 1, 2019, 00:00

  • Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model

    Dec 1, 2019, 00:00

  • Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis

    Dec 1, 2019, 00:00

  • Community-Based Services by Pharmacists: A Systematic Review of Cost-Utility Analyses

    Dec 1, 2019, 00:00

  • Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial

    Dec 1, 2019, 00:00

  • Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?

    Dec 1, 2019, 00:00

  • Copyright/Subscription

    Dec 1, 2019, 00:00

  • Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments? [Editor's Choice]

    Dec 1, 2019, 00:00

  • Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017

    Dec 1, 2019, 00:00

  • Carer Social Care-Related Quality of Life Outcomes: Estimating English Preference Weights for the Adult Social Care Outcomes Toolkit for Carers

    Dec 1, 2019, 00:00

  • Cost-Effectiveness of Antihypertensive Therapy in Patients Older Than 80 Years: Cohort Study and Markov Model

    Dec 1, 2019, 00:00

  • Editorial Board

    Nov 13, 2019, 17:52

  • CC2 ECONOMIC ASSESSMENT OF A HIGH DOSE VERSUS A STANDARD DOSE INFLUENZA VACCINE IN THE US VETERAN POPULATION: ESTIMATING THE IMPACT ON HOSPITALIZATION COST FOR CARDIOVASCULAR AND RESPIRATORY DISEASE

    Nov 1, 2019, 00:00

  • PCN178 MODELLING THE BUDGET IMPACT OF INTRODUCING 3D MAMMOGRAPHY FOR BREAST CANCER SCREENING IN GERMANY

    Nov 1, 2019, 00:00

  • PCN103 A COMPARISON OF PARTITIONED-SURVIVAL AND STATE TRANSITION MODELLING APPROACHES - FINDINGS FROM A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN80 REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2019, 00:00

  • PDB72 DEPRIVATION - MAIN CAUSE OF DIABETIC FOOT ULCER IN GERMANY

    Nov 1, 2019, 00:00

  • PDB57 COST SAVINGS ASSOCIATED WITH PREMIX VERSUS BASAL-BOLUS REGIMEN IN ALGERIAN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED UNDER BASAL INSULIN REGIMEN

    Nov 1, 2019, 00:00

  • PDB52 ECONOMIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDB123 CURRENT STATUS AND USE OF RESOURCES OF LYSOSOMAL STORAGE DISEASES: ANALYSIS OF A SPANISH CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PCN193 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND

    Nov 1, 2019, 00:00

  • PNS273 ICER: SIMILARITIES AND DIFFERENCES BETWEEN UK (ENGLAND) AND USA COST-EFFECTIVENESS WATCHDOGS

    Nov 1, 2019, 00:00

  • PMU29 ECONOMIC EVALUATION FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURES INFECTIONS (ABSSSI) FROM THE NATIONAL PAYER PERSPECTIVE: INTRODUCTION OF A NEW TREATMENT INTO THE PATIENT JOURNEY. SIMULATION IN 3 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PGI10 COST-UTILITY ANALYSIS OF USTEKINUMAB VS VEDOLIZUMAB IN CROHN DISEASE IN ITALY

    Nov 1, 2019, 00:00

  • PNS140 POTENTIAL IMPACTS OF THE U.K. VOLUNTARY SCHEME FOR BRANDED MEDICINES PRICING AND ACCESS: A REVIEW OF STAKEHOLDER OPINION

    Nov 1, 2019, 00:00

  • PMS52 CLINICAL GUIDELINE DEVELOPMENT FOR THE MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN PRIMARY CARE

    Nov 1, 2019, 00:00

  • PCV152 SELF-ASSESSED FUNCTIONAL CLASS, QUALITY OF LIFE AND HEALTHCARE RESOURCE CONSUMPTION IN PORTUGUESE HEART FAILURE PATIENTS: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • PUK12 ANALYSIS OF COST AND CONSEQUENCES RELATED TO THE PERSISTENCE OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS AND THEIR IMPACT ON QUALITY OF LIFE IN PATIENTS AGED ≥ 65 YEARS WITH OVERACTIVE BLADDER IN SPAIN

    Nov 1, 2019, 00:00

  • PMU100 A SYSTEMATIC REVIEW OF PREVIOUSLY PUBLISHED OR APPRAISED HEALTH ECONOMIC ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS

    Nov 1, 2019, 00:00

  • PNS291 ANALYSIS OF RECALLS OF MEDICAL DEVICES FROM 2009 TO 2018 BY RISK CLASS AND DEVICE CATEGORY BASED ON ITALIAN DATA

    Nov 1, 2019, 00:00

  • PCN370 IMPROVING PATIENT ACCESS TO INNOVATIVE MEDICATIONS WHILE PROTECTING PUBLIC BUDGETS SUSTAINABILITY: AN ALTERNATIVE GO TO MARKET AND PRICING FRAMEWORK TO ENABLE VALUE CO-CREATION BETWEEN PHARMAS AND PAYERS

    Nov 1, 2019, 00:00

  • PIH56 PLACE OF COMPLEMENTARY MEDICINES AND OPPORTUNITIES IN THE MANAGEMENT OF GYNECOLOGICAL CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PUK9 MEDICO-ECONOMIC EVALUATION OF HAEMODIAFILTRATION IN COMPARISON TO HIGH FLUX DIALYSIS

    Nov 1, 2019, 00:00

  • PRO132 DISEASE BURDEN OF X-LINKED HYPOPHOSPHATEMIA

    Nov 1, 2019, 00:00

  • PCN43 NEW CERVICAL CANCER SCREENING POLICY IN GERMANY - WHAT IS THE IMPACT ON THE BENEFIT-HARM BALANCE?

    Nov 1, 2019, 00:00

  • PMU4 WHAT IS A GOOD OR BAD NUMBER NEED TO TREAT (NNT) VALUE? A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS311 PREDICTIVE-ADJUSTED INDIRECT COMPARISON (PAIC): A NOVEL METHOD FOR POPULATION-ADJUSTED INDIRECT COMPARISON

    Nov 1, 2019, 00:00

  • PCN141 USE OF COST-EFFECTIVENESS AFFORDABILITY CURVES IN EVALUATING CANCER DRUGS IN ENGLAND

    Nov 1, 2019, 00:00

  • PCN487 COST OF PROSTATE CANCER AND QUALITY OF LIFE IN EGYPT - A PATIENT PERSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PIH61 VALIDATION OF THE STUDY MEDICATION SATISFACTION QUESTIONNAIRE (SMSQ). A MEASURE OF MEDICATION SATISFACTION DESIGNED FOR INDIVIDUALS TAKING PRE-EXPOSURE PROPHYLAXIS (PREP) MEDICATION FOR HIV

    Nov 1, 2019, 00:00

  • Alternative Medicine Nutrition - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV92 ANALYSING DATA OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO PROGRESSIVITY LEVELS IN HUNGARY (COMPARISON OF 2013 AND 2018)

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PNS347 SCIENTIFIC OUTCOME OF ISPOR CONFERENCES: AN ANALYSIS OF 44,390 ABSTRACTS PRESENTED AT 38 ISPOR CONFERENCES BETWEEN 2002-2018

    Nov 1, 2019, 00:00

  • PNS350 ANALYSIS OF HEALTH CARE WORKERS' MIGRATION: THE MOTIVATIONS OF HUNGARIAN PHISIOTHERAPISTS FOR WORKING ABROAD

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCV51 COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK

    Nov 1, 2019, 00:00

  • PNS182 SYSTEMIC ADMINISTRATION OF GLUCOCORTICOIDS IN GUIZHOU PROVINCE, CHINA: A SURVEY AMONG HOSPITAL PHARMACIES.

    Nov 1, 2019, 00:00

  • Alternative Medicine Nutrition - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN299 MINIMUM VOLUME STANDARDS IN FRENCH HOSPITALS FOR BREAST CANCER AND OVARIAN CANCER - INEQUALITIES IN ACCESS TO HOSPITAL CARE

    Nov 1, 2019, 00:00

  • PMU53 THE INCENTIVE FINANCIAL FRAMEWORK REGARDING FRENCH HOSPITAL PRESCRIPTION OF BIOSIMILAR MEDICINES WHEN DELIVERED IN RETAIL PHARMACY: IMPACT ANALYSIS OF ARTICLE 51 EXPERIMENTATION FOR 2018

    Nov 1, 2019, 00:00

  • PIN130 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA

    Nov 1, 2019, 00:00

  • PNS91 ACCESS AND UTILIZATION OF MATERNAL HEALTHCARE IN A RURAL DISTRICT IN THE FOREST BELT OF GHANA

    Nov 1, 2019, 00:00

  • PND9 UPDATED META-ANALYSIS OF THE EFFICACY OF ADJUVANT TREATMENT TO LEVODOPA IN PARKINSON'S DISEASE

    Nov 1, 2019, 00:00

  • PBI89 PHARMACOUTILIZATION OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED BY PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN AN ITALIAN REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • PCN244 BUDGETARY IMPACT OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PMD19 ECONOMIC EVALUATION OF CATARACT PHACOEMULSIFICATION IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PRO120 EVOLUTION OF OBCS NECESSARY TO ACTIVATE VALUE WITHIN STEM CELL RARE DISEASES

    Nov 1, 2019, 00:00

  • PMU87 REVIEW OF ORPHAN TREATMENTS ASSESSED BY NICE AND THE SMC IN THE UK.

    Nov 1, 2019, 00:00

  • PCN153 OVERVIEW OF ECONOMIC EVALUATIONS OF ONCOLOGY PRODUCTS WITH A FOCUS ON THE KEY CHALLENGES ACROSS, UNITED KINGDOM, FRANCE AND CANADA

    Nov 1, 2019, 00:00

  • PRO115 DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

    Nov 1, 2019, 00:00

  • PMU45 PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY

    Nov 1, 2019, 00:00

  • PND51 PRODUCTIVITY LOSS IN NHS HOSPITALS DUE TO DIFFICULT-TO-TREAT MIGRAINE

    Nov 1, 2019, 00:00

  • PPM6 HEALTH ECONOMICS MODEL OF FOUNDATIONONE CDX® IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN TURKEY

    Nov 1, 2019, 00:00

  • PRS21 PRODUCTIVITY LOSSES FOR ALLERGIC RHINITIS PATIENTS IN THE NETHERLANDS AND SWEDEN

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PRS48 UNLOCKING THE ACCESS CHALLENGES TO COPD

    Nov 1, 2019, 00:00

  • PNS57 BUDGET IMPACT ANALYSIS OF A WEARABLE REMOTE CONTINUOUS MONITORING DEVICE TO FACILITATE EARLY DISCHARGE OF BARIATRIC SURGERY PATIENTS IMMEDIATELY AFTER POSTOPERATIVE OBSERVATION IN THE RECOVERY WARD

    Nov 1, 2019, 00:00

  • PMU70 FACTORS INFLUENCING THE SELECTION OF PRODUCTS FOR THE ACCELERATED ACCESS COLLABORATIVE'S RAPID UPTAKE PATHWAY

    Nov 1, 2019, 00:00

  • PCN465 VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/ HER2- METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY

    Nov 1, 2019, 00:00

  • PNS371 EVALUATING QUALITY OF PRIMARY HEALTH CARE (PHC) SERVICES FROM THE PATIENTS' PERSPECTIVE IN GREECE

    Nov 1, 2019, 00:00

  • PCV61 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN TURKEY

    Nov 1, 2019, 00:00

  • PSY54 WEB SURVEY AND FOCUS GROUPS EXPLORING KNOWLEDGE, NEEDS AND EXPECTATIONS AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: PRELIMINARY RESULTS

    Nov 1, 2019, 00:00

  • PMU50 UNFOLD THE MYSTERY OF PRICE NEGOTIATION IN CHINA: HOW REIMBURSEMENT PAYMENT STANDARD WAS FORMULATED

    Nov 1, 2019, 00:00

  • PRS71 NEW METHODS FOR ANALYZING CLINICAL AND COST OUTCOMES IN ASTHMA WITH INTERACTIVE VISUAL ANALYTICS

    Nov 1, 2019, 00:00

  • PCN324 PRELIMINARY EVIDENCE SUGGESTS THAT WE MOVE TOWARDS THE USE OF LIQUID BIOPSIES TO PREDICT RESPONSE TO TKI INHIBITORS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PRS22 THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS

    Nov 1, 2019, 00:00

  • PNS53 REVIEW OF METHODOLOGICAL QUALITY OF BUDGET IMPACT ANALYSES FOR ORPHAN DRUGS

    Nov 1, 2019, 00:00

  • PUK39 URINARY TRACT INFECTIONS (UTIS) AFTER UROGENITAL PROCEDURES AND RELATED OUTCOMES AND COSTS: ANALYSIS OF DATA FROM THE NATIONAL HOSPITAL INFORMATION SYSTEM

    Nov 1, 2019, 00:00

  • PCN338 KEY DRIVERS OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR RELAPSED-REFRACTORY MULTIPLE MYELOMA TREATMENTS; A COUNTRY COMPARISON.

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCV141 ATHEROSCLEROSIS: REAL-WORLD INSIGHTS FROM A PORTUGUESE PRIMARY CARE DATABASE

    Nov 1, 2019, 00:00

  • PCN176 COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH+ CML-CP) IN ITALY

    Nov 1, 2019, 00:00

  • PSU40 PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE AFTER TOTAL JOINT REPLACEMENT: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMS12 PATIENTS PRESCRIBED WITH OPIOID TREATMENT IN PRIMARY CARE PRACTICES: A POPULATION-BASED STUDY IN ITALY

    Nov 1, 2019, 00:00

  • PIN115 ANALYZING SOCIO-ECONOMIC INEQUALITY IN CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA

    Nov 1, 2019, 00:00

  • PIT2 PATTERNS OF OPIOID USE FOLLOWING FRACTURE BASED ON TIME BETWEEN PRESCRIPTION ORDER AND PATIENT FILL

    Nov 1, 2019, 00:00

  • PAM15 PHOTOGRAPHIC FOOD DIARIES FOR NUTRITIONAL RESEARCH WITH CHILDREN AND HARD-TO-REACH POPULATIONS: A CASE STUDY EXPLORATION OF A NOVEL ASSESSMENT TOOL

    Nov 1, 2019, 00:00

  • PMU30 A SYSTEMATIC REVIEW OF PREVIOUSLY PUSBLISHED OR APPRAISED HEALTH ECONOMIC MODELS ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS

    Nov 1, 2019, 00:00

  • PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ALGERIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCV14 COMPARATIVE EFFECTIVENESS AND SAFETY OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A PROPENSITY SCORE-MATCHED COHORT STUDY

    Nov 1, 2019, 00:00

  • PCN411 HOW ARE SINGLE-ARM TRIALS PERCEIVED IN HEATH TECHNOLOGY ASSESSMENTS FOR CHRONIC LEUKAEMIA ACROSS THE EU5, AUSTRALIA AND CANADA?

    Nov 1, 2019, 00:00

  • Surgery - Economic Evaluation

    Nov 1, 2019, 00:00

  • Alternative Medicine Nutrition - Economic Evaluation

    Nov 1, 2019, 00:00

  • PDB9 SERUM GGT AND HSCRP: EARLY PREDICTORS OF OXIDATIVE STRESS AND INFLAMMATION IN TYPE 2 DIABETES MELLITUS PATIENTS WITH GOOD AND POOR GLYCEMIC CONTORL

    Nov 1, 2019, 00:00

  • PIN43 LIFECYCLE-MODEL-BASED ECONOMIC EVALUATION OF INFANT MENINGITIS B VACCINATION IN THE UK

    Nov 1, 2019, 00:00

  • PCN52 ABIRATERONE VERSUS ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY

    Nov 1, 2019, 00:00

  • PSU34 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A MEDICARE SUPPLEMENTAL DATABASE STUDY WITH TWO YEARS FOLLOW-UP

    Nov 1, 2019, 00:00

  • PND130 TREATMENT PATTERNS, HEALTH RESOURCES CONSUMPTION AND COSTS OF PATIENTS WITH MIGRAINE IN AN ITALIAN REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • PCN234 COST-EFFECTIVENESS ANALYSIS OF HOME-BASED PALLIATIVE CARE FOR END-STAGE CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PMU152 SWITCHING AMONG BIOLOGIC THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PMU68 THE ROLE OF OUTCOMES-BASED MODELS FOR THE REIMBURSEMENT OF MEDICINES IN THE UK NATIONAL HEALTH SERVICE

    Nov 1, 2019, 00:00

  • PIN2 EFFECTIVENESS AND SAFETY OF DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS INFECTED PATIENTS AFTER LIVER TRANSPLANTATION. RESULTS IN REAL CLINICAL PRACTICE.

    Nov 1, 2019, 00:00

  • PNS396 VALUING HEALTH RELATED QUALITY OF LIFE IN MOROCCO: AN EQ-5D-3L VALUE SET

    Nov 1, 2019, 00:00

  • PRO17 A BUDGET IMPACT ANALYSIS OF ANTI-INHIBITOR COAGULANT COMPLEX USE IN PEDIATRIC HEMOPHILIA A PATIENTS WITH INHIBITORS ACROSS KINGDOM OF SAUDI ARABIA.

    Nov 1, 2019, 00:00

  • PIN44 COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM

    Nov 1, 2019, 00:00

  • PCN18 CLINICAL BENEFITS OF REHABILITATION IN PATIENTS WITH ADVANCED CANCER IN KOREA

    Nov 1, 2019, 00:00

  • PCN503 USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH TO INFORM TREATMENT DECISIONS AMONG US ONCOLOGISTS

    Nov 1, 2019, 00:00

  • PCV27 AN ECONOMIC ANALYSIS OF ENDOVASCULAR ARTERIOVENOUS FISTULAS IN DIALYSIS PATIENTS: A U.S. PAYER AND PROVIDER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRO10 QUALITATIVE STUDY TO ESTABLISH THE CONTENT VALIDITY OF THE ABC-CFXS FOR EVALUATION OF TREATMENT EFFICACY IN FRAGILE X SYNDROME

    Nov 1, 2019, 00:00

  • PCN306 THE MODEL OF OUTCOMES-BASED RISK SHARING AGREEMENTS APPLIED TO TARGETED DRUGS IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS359 INTERNATIONAL OBSERVATIONAL STUDIES: THE INCREASED NEED FOR A COMMON EUROPEAN REGULATION

    Nov 1, 2019, 00:00

  • Comparative Effectiveness or Efficacy Studies

    Nov 1, 2019, 00:00

  • PNS109 PERCEPTIONS AND PRACTICES OF SELF- MEDICATION IN AN INDIAN URBAN COMMUNITY

    Nov 1, 2019, 00:00

  • PIN64 COST OF HEPATITIS C VIRUS ERADICATION: ECONOMIC MODEL CONCEPT

    Nov 1, 2019, 00:00

  • PCN55 NETWORK META-ANALYSIS COMPARING PALBOCICLIB PLUS FULVESTRANT WITH EVEROLIMUS PLUS EXEMESTANE FOR HR+/HER2- ADVANCED BREAST CANCER THAT HAS BECOME RESISTANT TO PREVIOUS ENDOCRINE THERAPY

    Nov 1, 2019, 00:00

  • PIN105 DESCRIPTION OF PATIENTS HOSPITALIZED WITH MENINGOCOCCAL INFECTIONS IN FRANCE: AN ANALYSIS OF THE NATIONAL HEALTHCARE CLAIM(SNIIR-AM) DATABASE

    Nov 1, 2019, 00:00

  • PDB76 IMPACT OF COPAYMENT INCREASE OF ANTIDIABETIC MEDICATIONS ON GLYCAEMIC CONTROL IN FINNISH PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PCN285 THERAPEUTIC BENEFIT OF ORPHAN DRUGS IN ONCOLOGY: EVIDENCE AT THE POINT OF EUROPEAN MARKETING AUTHORISATION

    Nov 1, 2019, 00:00

  • PCN144 ECONOMIC EVALUATIONS OF CANCER INTERVENTIONS IN SPAIN: LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Alternative Medicine Statistical Research

    Nov 1, 2019, 00:00

  • PMS59 REAL-WORLD EFFECTIVENESS OF PHYSIOTHERAPY INTERVENTIONS FOR MUSCULOSKELETAL DISORDERS IN NIGERIA

    Nov 1, 2019, 00:00

  • PDG78 IMPACT OF FIRST RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) FROM EUNETHTA ON DRUG HTA ASSESSMENTS BY HAS, IQWIG AND NICE

    Nov 1, 2019, 00:00

  • PMU66 TIMEFRAME FOR DRUG MARKETING AUTHORIZATION IN EUROPE

    Nov 1, 2019, 00:00

  • PNS397 PATIENTS' PERCEPTION OF THE QUALITY OF CONSULTATIONS MODELLED BY PATIENT-REPORTED EXPERIENCE AND HEALTH-RELATED QUALITY OF LIFE MEASURES

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PDB39 INSULIN PRICE FLUCTUATION IN THE USA BETWEEN JULY 2017 AND JULY 2019

    Nov 1, 2019, 00:00

  • PMS38 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN COMPARISON WITH ANAKINRA IN SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS (SJIA) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PCV46 BUDGET IMPACT OF A DUAL-LAYER STENT RETRIEVER (DLSR) IN THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS) FROM HOSPITAL'S PERSPECTIVE IN FRANCE AND SWEDEN

    Nov 1, 2019, 00:00

  • PGI58 A STUDY OF LONG TERM HOSPITALIZATION COSTS IN PATIENTS WITH ULCERATIVE COLITIS USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCN143 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL

    Nov 1, 2019, 00:00

  • Mental Health - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PNS38 PROPOSING AND EVALUATING A DESIGN FOR GDPR-COMPLIANT, SCALABLE TECHNOLOGY FOR AUTOMATIC ADJUDICATION OF RISK-SHARING AGREEMENTS

    Nov 1, 2019, 00:00

  • PCN258 APPLYING BIG DATA ANALYTICS TO DEVELOP PREDICTIVE MODELS FOR ESTIMATING HER2+ BC INCIDENCE AND PREVALENCE IN BRAZIL

    Nov 1, 2019, 00:00

  • PCN443 INDIRECT COMPARISON BETWEEN REAL WORLD DATA AND CLINICAL TRIAL IN NON SMALL CELL LUNG CANCER WITH BEVACIZUMAB

    Nov 1, 2019, 00:00

  • PCN259 SKELETAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: EMERGING TRENDS FROM THE US FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM

    Nov 1, 2019, 00:00

  • PCN353 RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON NON-SMALL CELL LUNG CANCER: RESULTS, RATIONALE, AND TRENDS

    Nov 1, 2019, 00:00

  • PDG36 ANALYSIS OF GABAPENTINOIDS ABUSE IN THE MIDDLE EAST AND NORTH AFRICA REGION UTILIZING THE FOOD AND DRUG ADMINISTRATION ADVERSE EVENTS REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • Mental Health - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PND72 EVOLUTION OF THE CONSUMPTION OF ANTIEPILETEC DRUGS IN MOROCCO FROM 2004 TO 2016

    Nov 1, 2019, 00:00

  • PCN500 REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN BRAZIL

    Nov 1, 2019, 00:00

  • PCN407 SOMATOSTATIN ANALOGUES IN IMAGING OF BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PIT10 THE INCREMENTAL COST OF TRAUMATIC BRAIN INJURY DURING THE FIRST YEAR AFTER A ROAD TRAFFIC ACCIDENT IN BELGIUM

    Nov 1, 2019, 00:00

  • PIN70 COST-EFFECTIVENESS OF SEASONAL VACCINATION WITH QUADRIVALENT INFLUENZA VACCINE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PIN60 COMPARISON OF ANTI-HIV AND ANTI-HCV THERAPY COSTS IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN436 RESPONSIVENESS OF THE EQ-5D-5L AND EORTC QLU-C10D IN CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PMU130 REPRESENTATIVENESS OF THE NATIONAL HEALTH AND WELLNESS SURVEY IN EUROPE: CURRENT EPIDEMIOLOGY ACROSS MULTIPLE DISEASES

    Nov 1, 2019, 00:00

  • PMS74 TAPERING BIOLOGIC? AN INSIGHT AND PERSPECTIVE OF RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2019, 00:00

  • PRO44 THE ECONOMIC IMPACT AND HEALTH-RELATED QUALITY OF LIFE OF SPINAL MUSCULAR ATROPHY (SMA). AN ANALYSIS ACROSS THREE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PCV17 HEALTHCARE UTILIZATION PRIOR TO AN INITIAL DIAGNOSIS OF PAROXYSMAL SUPRVENTRICULAR TACHYCARDIA IN A LARGE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PCN185 PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS: A 4-YEAR EXPERIENCE

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PMU43 A MORE ACCURATE MEASURE OF AFFORDABILITY OF ALCOHOL FOR THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • Medical Devices - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCN356 ARE CANCER DRUGS ASSOCIATED WITH A COMPANION DIAGNOSTIC TEST TAKING LONGER TO BE REIMBURSED IN AUSTRALIA?

    Nov 1, 2019, 00:00

  • PMU137 A BIBLIOMETRIC ANALYSIS OF SOUTH AFRICAN HEALTH-RELATED QUALITY OF LIFE STUDIES RELEVANT TO ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PR4 TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION (TSQM - VERSION 1.4): CEILING AND FLOOR EFFECTS, RELIABILITY AND CONSTRUCT VALIDITY

    Nov 1, 2019, 00:00

  • PRO56 ECONOMIC IMPACT OF THE INTRODUCTION OF RFVIII-SINGLECHAIN (AFSTYLA®) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY

    Nov 1, 2019, 00:00

  • CP2 DO SOCIAL VALUES AND INSTITUTIONAL CONTEXT IMPACT THE USE OF ECONOMIC EVALUATION IN PRIORITY SETTING: EMPIRICAL EVIDENCE FROM OECD COUNTRIES

    Nov 1, 2019, 00:00

  • PDG2 METHYLNALTREXONE FOR OPIOID-INDUCED CONSTIPATION IN PATIENTS RECEIVING PALLIATIVE CARE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • Personalized Process of Care

    Nov 1, 2019, 00:00

  • PRO85 THE APPRAISAL PROCESS OF HIGH COST DRUGS FOR RARE GENETIC DISEASES IN THE PUBLIC HEALTH SYSTEM IN BRAZIL

    Nov 1, 2019, 00:00

  • PNS343 THE COMPLETENESS OF CLINICALTRIALS.GOV. - WHAT IS THE RATE OF PUBLISHED CLINICAL TRIALS REGISTERED ON THE WEBSITE?

    Nov 1, 2019, 00:00

  • PCN284 PRESCRIBING TRENDS ACROSS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CANCER IN IRELAND

    Nov 1, 2019, 00:00

  • PND47 CLADRIBINE TABLET, AS A DOMINANT COMPARATOR TO NATALIZUMAB IN HIGH-DISEASE ACTIVITY RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN THE CONTEXT OF A DEVELOPING COUNTRY

    Nov 1, 2019, 00:00

  • PCN218 COST-EFFECTIVENESS OF APALUTAMIDE + ADT VERSUS ENZALUTAMIDE + ADT IN NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER IN GREECE

    Nov 1, 2019, 00:00

  • PIN114 UNDERSTANDING CHANGES IN FULL CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA BETWEEN 2000 AND 2016: OAXACA-BLINDER DECOMPOSITION ANALYSIS

    Nov 1, 2019, 00:00

  • PDB16 ASSESSMENT OF COST-EFFECTIVENESS OF A 0.2 ΜCG/DAY FLUOCINOLONE ACETONIDE (FAC) IMPLANT IN PATIENTS WITH CHRONIC DIABETIC MACULAR OEDEMA (DMO) IN AN EYE WITH CATARACT

    Nov 1, 2019, 00:00

  • PMH2 BREXANOLONE INJECTION IN POSTPARTUM DEPRESSION: SUSTAINED REMISSION, SUSTAINED RESPONSE, AND NUMBER NEEDED TO TREAT

    Nov 1, 2019, 00:00

  • PCN357 PREDICTOR OF A POSITIVE RECOMMENDATION IN NICE ONCOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PMH66 COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HCRU) AND EXPENDITURES AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MEDICATION-ASSISTED TREATMENT (MAT) RECEIVED

    Nov 1, 2019, 00:00

  • PDB41 HOW ECONOMIC ANALYSIS INCREASE AWARENESS ON CLINICAL SERVICE, A CASE OF DIABETES MELLITUS AT A TEACHING HOSPITAL IN MYANMAR

    Nov 1, 2019, 00:00

  • PSY17 REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA

    Nov 1, 2019, 00:00

  • PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D)

    Nov 1, 2019, 00:00

  • PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PBI65 ASSESSMENT OF WILLINGNESS TO PAY IN A RAPIDLY INCREASING BIOLOGICS MARKET FOR RESPIRATORY DISEASES

    Nov 1, 2019, 00:00

  • PND102 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PDG98 A DISPROPORTIONALITY ANALYSIS OF SPONTANEOUS ADVERSE EVENT REPORTS FOR OSTEONECROSIS OF JAW ATTRIBUTED TO AROMATASE INHIBITORS IN FDA ADVERSE EVENTS REPORTING SYSTEM

    Nov 1, 2019, 00:00

  • PRO107 UNDERSTANDING THE PRICING AND REIMBURSEMENT (PR) LANDSCAPE OF ORPHAN DRUGS IN EMERGING MARKETS

    Nov 1, 2019, 00:00

  • PCN414 INCLUSION OF SUBSEQUENT TREATMENTS WITH CURATIVE INTENT IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PARTITIONED SURVIVAL MODELS

    Nov 1, 2019, 00:00

  • PCN444 DYNAMIC SURVIVAL MODELS FOR INCORPORATING EXTERNAL EVIDENCE WHEN EXTRAPOLATING OVERALL SURVIVAL: A CASE STUDY.

    Nov 1, 2019, 00:00

  • PCV100 THE RELATIONSHIP BETWEEN PROCEDURAL VOLUME AND POSTOPERATIVE MORTALITY FOR PERCUTANEOUS CORONARY INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS

    Nov 1, 2019, 00:00

  • PCN419 THE USE OF INDIVIDUAL PATIENT-LEVEL DATA (IPD) TO CONDUCT INDIRECT TREATMENT COMPARISONS (ITCS) IN SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PIH28 A REAL WORLD ANALYSIS OF PREVALENCE OF SYMPTOMS AND HEALTHCARE UTILIZATION IN WOMEN WITH MENOPAUSE

    Nov 1, 2019, 00:00

  • PDG104 DECREASING NUMBER OF PRESCRIPTIONS AFTER THEY BECAME MANDATORY AND THEIR VALIDITY PERIOD WAS EXTENDED TO TWO YEARS: CASE FINLAND SINCE 2017

    Nov 1, 2019, 00:00

  • PDB125 PREDICTING NASH PATIENTS USING INNOVATIVE MACHINE LEARNING TECHNIQUES

    Nov 1, 2019, 00:00

  • PRO105 A REVIEW OF SIX YEARS OF THE NICE HIGHLY SPECIALISED TECHNOLOGY (HST) PROGRAMME

    Nov 1, 2019, 00:00

  • Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention

    Nov 1, 2019, 00:00

  • PCN496 BURDEN OF ACUTE MYELOID LEUKEMIA AMONG NEWLY DIAGNOSED PATIENTS IN SOUTH KOREA: RETROSPECTIVE EMR DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • PMU140 A COMPREHENSIVE CATALOGUE OF EQ-5D SCORES IN CHRONIC DISEASE: RESULTS OF A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PRS69 TREATMENT OF COPD PATIENTS IN GERMANY AND THE NEED FOR THERAPY ESCALATION: A CLAIMS DATA ANALYSIS

    Nov 1, 2019, 00:00

  • PND43 BUDGET IMPACT OF THE INTRODUCTION OF ALEMTUZUMAB IN NORWAY; A REAL WORLD EVIDENCE ANALYSIS USING DATA FROM THE NORWEGIAN PATIENT REGISTRY, THE NORWEGIAN PRESCRIPTION DATABASE, AND IMS SALES DATA

    Nov 1, 2019, 00:00

  • PNS235 ASSESSMENT OF DIGITAL HEALTH TECHNOLOGIES - COMPARISON OF EVIDENCE FRAMEWORKS OF NICE AND HAS

    Nov 1, 2019, 00:00

  • PCN422 BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMAB

    Nov 1, 2019, 00:00

  • PCN400 ONCOLOGY-RELATED HTA DECISIONS IN GERMANY, FRANCE, SPAIN AND THE UK: ASSESSMENT OF SIMILARITIES AND DIFFERENCES

    Nov 1, 2019, 00:00

  • PNS288 ANALYSIS OF RECENT TRENDS IN E-HEALTH SOLUTIONS DEVELOPED BY PHARMACEUTICAL AND BIOTECH COMPANIES

    Nov 1, 2019, 00:00

  • PIN153 HEALTH OUTCOMES AND HEALTH SYSTEM COSTS ASSOCIATED WITH SEPSIS: A POPULATION-BASED, RETROSPECTIVE COHORT STUDY

    Nov 1, 2019, 00:00

  • PNS18 CAN REFLECTIVE MCDA CONTRIBUTE TO ACHIEVING EMA'S STRATEGIC OBJECTIVES FOR REGULATORY SCIENCE TO 2025? WHEN THE BOTTOM UP APPROACH CAN BE THE WAY TO GO: INSIGHTS FROM SPANISH EXPERIENCE

    Nov 1, 2019, 00:00

  • PND80 HEALTHCARE UTILISATION AND PERCEIVED HEALTH NEEDS OF MULTIPLE SCLEROSIS PATIENTS IN GREECE: EVIDENCE FROM A QUALITATIVE STUDY

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44 (current)
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • »